I receive notices from Prostate Cancer Today and this caught my eye.

Prostate Cancer Today

Source – Prostate Cancer News Today – Apr 12 2019

ADXS-PSA/Keytruda Combo Prolongs Survival In mCRPC, Early trial Results Suggest

Adding ADXS-PSA, an investigational cancer vaccine, to Keytruda(pembrolizumab) is showing positive signs of safety and efficacy in patients with metastatic, castration-resistant prostate cancer(mCRPC), and appears to prolong survival compared with standard-of-care therapy, early results from an ongoing Phase 1/2 trial show.The results were announced by Advaxis, the company developing ADXS-PSA, and presented in a poster at the recent American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta. Its title was “Effects of ADXS-PSA With or Without 

Not sure if this adds to the perspective on the competitiveness of prostate cancer options.

GLTA

Toinv